Matches in Nanopublications for { ?s ?p "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867734.RADJG5-S62a6-HbkLby9cTDDS09qfe-hoJ2TSkfGn1flY130_provenance.
- NP867733.RAtG04VjiDyzIsxPWdBv0bk2E2I37YJD9uJZIDT8FAIdg130_assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867733.RAtG04VjiDyzIsxPWdBv0bk2E2I37YJD9uJZIDT8FAIdg130_provenance.
- NP867731.RANDNX0tGk1-enYADdTTZiytxuz7YUdw5eoS66Toj6fVA130_assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867731.RANDNX0tGk1-enYADdTTZiytxuz7YUdw5eoS66Toj6fVA130_provenance.
- NP867736.RA6011SgRB5zzyLJsXvVsXBHWN3iAzo98r3tV3XQAtsYw130_assertion description "[The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867736.RA6011SgRB5zzyLJsXvVsXBHWN3iAzo98r3tV3XQAtsYw130_provenance.